BMY ▲ +4.6% - Bristol-Myers Squibb Company $BMY Bristol Myers Squibb: Phase 3 ALOFT-IPF Trial of Admilparant Meets Primary Endpoint at 60 mg Dose ? • 60 mg twice-daily dose showed a statistically significant improvement vs. placebo in FVC change at Week 52; the 120 mg dose slowed FVC decline but was not statistically significant. • Admilparant was well tolerated across both doses, with discontinuations due to adverse events low and similar to placebo. • Bristol Myers plans regulatory discussions and submissions; detailed results will be presented at a future medical meeting. 12-OCT-2026 06:57 AM ET